Plumiaz (diazepam nasal spray) / Acorda - LARVOL DELTA

Acorda Therapeutics to present at the Cowen & Company 34(th) Annual Health Care Conference (The Wall Street Journal) - “Acorda Therapeutics…will present at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3 at 4:10 pm ET at the Marriott Copley Plaza Hotel in Boston.”

Anticipated conference • Epilepsy

Acorda Therapeutics to present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences in February (Businesswire) - “Acorda Therapeutics...announced that it will present at the Citi 2013 Global Healthcare and RBC Capital Markets conferences in February.”

Anticipated conference • Epilepsy

Descriptor-Based Approach for the Prediction of Cation Vacancy Formation Energies and Transition Levels. (PubMed, J Phys Chem Lett) - "We apply our model to ordered alloys within the CdZnSeTe, CdZnS, and ZnMgO systems and predict the positions of cation vacancy charge-state transition levels with a mean absolute error of <0.2 eV compared to the explicitly calculated values, showing useful accuracy without the need for the expensive and large-scale calculations typically required. This suggests the properties of other point defects may also be predicted with useful accuracy from only bulk-derived properties."

Journal • Biosimilar • Ophthalmology

Acorda presents new data on diazepam nasal spray at 67th Annual Meeting of American Epilepsy Society (Acorda Press Release) - P2, N=31; NCT01417078; Sponsor: Acorda; “The overall safety and tolerability of Diazepam Nasal Spray in this study was consistent with systemic diazepam exposure established with other diazepam products. The most common local adverse events were related to the nasal route of delivery; most adverse events were mild and transient, and resolved within a day....Acorda has submitted a New Drug Application for Diazepam Nasal Spray to the U.S. Food and Drug Administration (FDA) and will rely upon the FDA’s previous findings of safety and efficacy for diazepam rectal gel.”

NDA • P2 data • Epilepsy

A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=15; Completed; Sponsor: Acorda Therapeutics; Active, not recruiting ➔ Completed

Trial completion • Biosimilar

Ultralow Threshold One-Photon- and Two-Photon-Pumped Optical Gain Media of Blue-Emitting Colloidal Quantum Dot Films. (PubMed) - "Utilizing these QDs, we also report one-photon-absorption-pumped ASE at an ultralow threshold of ∼60 μJ/cm(2), which is comparable to the state-of-the-art red-emitting QD-based gain media. This one-photon-pumped ASE threshold is an order of magnitude better than that of the previously reported best blue-emitting QD-based gain media."

Journal • Biosimilar

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults With Cluster Seizures (clinicaltrials.gov) - P2; N=126; Terminated; Sponsor: Acorda Therapeutics; Completed ➔ Terminated

Trial termination • Biosimilar • Epilepsy

Acorda Therapeutics to present at the Credit Suisse 2014 Healthcare Conference (Acorda Press Release) - “Acorda Therapeutics…announced that Michael Rogers, Chief Financial Officer will present at the Credit Suisse 2014 Healthcare Conference in Phoenix on Tuesday, November 11 at 3:30pm MT.”

Anticipated conference • Epilepsy